EM
BCRX icon

ELCO Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

ELCO Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-30,792
Closed -$190K – 166
2024
Q2 		$190K Sell
30,792
-5,229
-15% -$28.9K 0.11% 145
2024
Q1 		$183K Buy
36,021
+5,368
+18% +$30.2K 0.11% 142
2023
Q4 		$184K Sell
30,653
-1,158
-4% -$6.71K 0.12% 132
2023
Q3 		$225K Buy
31,811
+18,269
+135% +$131K 0.16% 112
2023
Q2 		$95.3K Buy
+13,542
New +$109K 0.07% 123

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

ELCO Management's BCRX Position: Q3 2024 in Review

ELCO Management sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2024, closing a stake of 30,792 shares — an estimated $190K sold.

ELCO Management first reported a position in BCRX in Q2 2023 and held it in 5 quarters. The position peaked at $225K in Q3 2023. 257 funds tracked by Wall St. Rank hold BCRX as of Q3 2024.

  • ELCO Management reported no remaining BioCryst Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • ELCO Management sold 30,792 BioCryst Pharmaceuticals shares in Q3 2024, an estimated $190K.
  • ELCO Management first reported a position in BioCryst Pharmaceuticals in Q2 2023 and held it in 5 quarters.
  • ELCO Management's BioCryst Pharmaceuticals position peaked at $225K in Q3 2023.
  • 257 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2024.

Based on ELCO Management's 13F filing for Q3 2024, filed 14 Nov 2024.